NE
Nectar Lifesciences Limited
NECLIFE.NS · NSE
₹12.30 +1.91% (+₹0.23)
1M +15.06%
Market Cap ₹2.37B
P/E Ratio -
Div. Yield -
ROE 32.98%
Bulios Fair Price
₹15.2
23.6% upside
Current Price
₹12.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NECLIFE.NS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
66 /100
Fair EV/EBITDA 14.97x
P/S 31.89x
P/B 0.41x
Growth
0 /100
Declining Book val. growth 18.22%
EPS growth N/A
Rev. growth N/A
Profitability
30 /100
Weak Gross margin 762.14%
Net margin 3,292.51%
Op. margin 1,171.85%
Quality
19 /100
Poor ROIC 8.32%
ROE 32.98%
ROA 39.42%
Debt
81 /100
Low Debt/Equity 0.00x
Current ratio 8.40x
Int. coverage 0.22x
Stability
26 /100
Unstable Beta 0.65x
Rev. volatility 60.80%
EPS volatility 1,451.92%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NECLIFE.NS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Sanjiv Goyal
Employees
111
Headquarters
Chandigarh